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Practice
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Five things to know about …

Myotonic dystrophy type 1
Cam-Tu Emilie Nguyen MD, Craig Campbell MD MSc

Myotonic dystrophy type 1 is a common form of muscular dystrophy

The prevalence of myotonic dystrophy
type 1 ranges between 0.5 and 18.1 per
100 000 population, making it the most
common muscular dystrophy, ahead of
Duchenne and facioscapulohumeral
muscular dystrophies.1 Myotonic dystrophy type 1 is especially prevalent in certain regions of Quebec.2 It is an autosomal dominant nucleotide repeat disorder.
The mutant messenger RNA with
expanded repeats has a toxic gain of
function, resulting in widespread splicing dysregulation.
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Myotonic dystrophy type 1 shows
genetic anticipation

Genetic anticipation, the earlier and
more severe presentation in offspring,
relates to the unstable trinucleotide
repeat mutation expanding in subsequent generations. Congenital myotonic dystrophy type 1 is the most
severe manifestation of this disorder.
Congenitally affected neonates with
this manifestation are weak and hypotonic, and often require ventilation
and feeding support. Mortality is
about 25% in the first year.4 Strength
and ability to feed and breathe
improve in those who live beyond the
first year.
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Myotonic dystrophy type 1 is multisystemic
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Myotonic dystrophy type 1 can present at any age but is typically diagnosed in
adults. Although this disorder can present in many different ways (Appendix 1,
available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.151384/-/DC1), facial
and distal muscle weakness, along with grip myotonia, are key findings on examination. Given the risk of sudden death (described below), dominant inheritance
and high penetrance,3 first-degree relatives and women of childbearing age who
are at risk of carrying an affected child should be referred for genetic counselling.

Cardiac arrythmia is a frequent
cause of death
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Unlike other dystrophies, arrhythmias
and other conduction abnormalities are
the primary cardiac manifestation in
myotonic dystrophy type 1 and require
regular electrocardiographic (ECG)
monitoring and referral to cardiology.5
Sudden cardiac death may be predicted
by severe abnormalities detected through
ECG monitoring and a diagnosis of
symptomatic atrial tachyarrhythmias.5
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Treatments are symptomatic

No treatment to modify disease currently exists. However, mexiletine is
effective in reducing myotonia based
on evidence from randomized controlled trials (RCTs).6 In a small RCT,
methylphenidate was found to
decrease excessive somnolence seen
in this disorder.7 There are some
promising disease-modifying therapies entering clinical trials.
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